
Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target
Oric Pharmaceuticals (ORIC) Analyst Ratings
Bulls say
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company with a diverse pipeline of therapies targeting resistance mechanisms in cancer. The company's focus on hormone-dependent cancers, precision oncology, and key tumor dependencies, paired with a 35-40% probability of approval for its lead candidates in various cancer indications, presents a strong investment opportunity. Risks include clinical failure, delays in pivotal trials, and slower market uptake, but a discounted cash flow-based valuation yields a price objective of $25 per share.
Bears say
ORIC Pharmaceuticals is facing two main challenges that may have contributed to the recent decline in its stock price: the voluntary withdrawal of Tazverik from the market due to safety concerns and delays in clinical trials. However, these issues may be specific to Tazverik and not indicative of the company's overall pipeline. With promising data from its other product candidates and a strong balance sheet, investors could see a buying opportunity at the current dip in the stock price.
This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction
Start investing in Oric Pharmaceuticals (ORIC)
Order type
Buy in
Order amount
Est. shares
0 shares